InYourFaceTomSelleck
Posted - 1 week ago
$COLL dumping. I'm out. Great fundamentals but what a f***** up company
swingingtech
Posted - 2 weeks ago
$CORT $IONS $COLL
https://wallstreetwaves.com/corcept-therapeutics-stock-surges-61-in-2024-a-must-buy/
Estimize
Posted - 2 weeks ago
Wall St is expecting 1.59 EPS for $COLL Q3 [Reporting 11/07 AMC]
http://www.estimize.com/intro/coll?chart=historical&metric_name=eps&utm_co
WeeklyTrader
Posted - 10/23/24
Let’s talk about the red flags for $COLL! RSI: 41.34% 50-day MA: $37.63 200-day MA: $35.44
jewell69
Posted - 4 weeks ago
10/21 $COLL B 223 36.84
Re entry
jewell69
Posted - 1 month ago
$NTRB ?? Threat to $COLL ???
I need to study
Kid sister has been trading it 4 2 yrs+
But nothing in the last 129 days
WeeklyTrader
Posted - 1 month ago
Stay cautious! Grab a PUT on $COLL at strike 35.0p! RSI: 49.66% 50-day MA: $37.26 200-day MA: $35.26
jewell69
Posted - 1 month ago
$COLL conflictin views since 9/4 1 says keep; 1 says buy S just now 10/14 12:33 pm EDT BLENDED 37.95 & .93 JUST 222 in kid sisters account b 10/10 36.35
jewell69
Posted - 1 month ago
$COLL 2 b fair dated 9/4/24 Collegium Pharmaceutical price target raised to $50 from $47 at H.C. Wainwright 10/11/24 close 37.72
jewell69
Posted - 1 month ago
$COLL NOT so nice news Hold rating on Collegium Pharmaceutical (COLL – Research Report) today and set a price target of $37.00. The company’s shares closed yesterday (10/11) at $36.64. Amsellem covers the Healthcare sector, focusing on stocks such as Corcept Therapeutics, Teva Pharmaceutical, and Alkermes. insider activity of 35 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of COLL in relation to earlier this year. Last month, Thomas B Smith, the EVP and Chief Medical Officer of COLL sold 9,593.00 shares for a total of $351,295.66. non addictive pain medicine; many diabetes people w/ neuropat_y take it. (more and more users.) Livin_ in luxury on pain and sufferin_ of diabetics. I want out on Monday 10/14 ! b 10/10/24 Shares +222.000 Price $36.33 Amount -$8,064.19 10/11/24 friday close 37.72
jewell69
Posted - 1 month ago
$COLL RE-ENTRY TODAY 10/10/24 Oct-10-2024 01:15:17 PM ET $36.3252 222.000 $8,064.19
jewell69
Posted - 1 month ago
$COLL TRYIN 2 RE-ENTER AT 36.25 LAST TRADE 36.30 MORE EXPENSIVE T_AN I SOLD IN JULY ? UNDERSTAND ? 07/24/2024 Sell Trade Details COLL COLLEGIUM PHARMACEUTICAL 143 $34.20 $0.16 $4,890.44 07/23/2024 Sell Trade Details COLL COLLEGIUM PHARMACEUTICAL 200 $33.6001 $0.22 $6,719.80 07/17/2024 Buy Trade Details COLL COLLEGIUM PHARMACEUTICAL 200 $31.96 -$6,392.00 07/11/2024 Sell Trade Details COLL COLLEGIUM PHARMACEUTICAL 50 $32.06 $0.05 $1,602.95
jewell69
Posted - 1 month ago
$COLL 9/4/24 9/3 clos price: ~ 37.45 now 10/10/24 1:08 pm EDT 36.33 H.C. Wainwright analyst Oren Livnat raised the firm's price target on Collegium Pharmaceutical to $50 from $47 and keeps a Buy rating on the shares after the company announced the closing of the Ironshore acquisition. The company issued updated 2024 guidance to include a partial year of Jornay PM sales that is ahead of estimates, the analyst tells investors in a research note. The firm increased forward revenue and margin estimates for Collegium on likely better Jornay PM economics than previously assumed.
kgnfdeagle
Posted - 1 month ago
$COLL Bought at $37.25; 100 share starter position.
GreenDotStocks
Posted - 1 month ago
Collegium Pharmaceutical ($COLL) develops and markets medicines for pain management, focused largely on extended release formulations of addictive opioid-based drugs. Currently, the firm sells 3 drugs, each contributing about 30% of revenue. Xtampza ER is an extended release version of oxycodone. Nucynta ER is a similar formulation of tapentadol, another powerful opioid. Belbuca is a form of buprenorphine, a synthetic opioid that can also be highly addictive. I have a few concerns with investing in this one. First, after the recent purchase of Ironshore to add ADHD drug Journay ER, Collegium will have a substantial amount of debt and only about a 2x interest coverage ratio (that's risky). Second, there is board room drama, with former CEO Joe Ciaffoni forced out in May by founder Michael Heffernan. And finally, about 1/3rd of current sales are at risk in the next few years as Nucynta goes off-patent. Just too many issues with this one. I'm passing on adding it to the Watch List.
FlynancialAnalyst
Posted - 1 month ago
$COLL fresh ATH in this #ShortSqueeze setup. DD ^^ in thread above remains mostly unchanged
Cousin_Vinny
Posted - 1 month ago
$COLL #Collegium Pharma b/o #IBDPartner from my #MVP scan, which looks for PE < 10 w/ increasing revenues, increasing fund ownership YoY for 3 years. Growth rate > 50% That said, debt is a bit high (negative point). @InvestorsBusinessDaily @MarketSurge Side note: Great numbers (different scan) for $NVDA $PLTR $META 3 of 6 that #TomLee recommends at @ Fundstrat.com . @MarketSurge dirt cheap $$ https://tinyurl.com/MktSurge
Doozio
Posted - 1 month ago
$COLL da FUTUre of 🧠⏰ is NOW during 🧠⏰♾️
Shlobby
Posted - 09/23/24
Can we just start $coll ecting money and get out of this range
FlynancialAnalyst
Posted - 09/22/24
$COLL $1.25B mc $XLV #ShortSqueeze screen result knocking on ATHs $40+ just above freshly rising 10/40/80 wk SMAs Pct of all funds long shares is at RECORD highs & rising Short float % is now rolling over from 24.75% highs This could EASILY squeeze to $100 TrendEdge.app/asset/COLL
InsiderPeek
Posted - 2 months ago
$COLL Chief Medical Officer Smith Thomas B sold 9.6k shares for $351.3k (ownership down 15.13%) insiderpeek.com/company/COLL
Doozio
Posted - 2 months ago
$COLL da FUTUre of 🧠⏰♾️ is NOW
StockInvest_us
Posted - 2 months ago
Signal alert: $COLL - Double Top https://stockinvest.us/l/VZugGp03Za
bigkahunatrader
Posted - 2 months ago
$COLL Collegium Pharmaceutical CAT-3 TM-2 Cycle https://youtube.com/shorts/WuYl-pe2zOk?feature=share
StockInvest_us
Posted - 2 months ago
Signal alert: $COLL - Double Top https://stockinvest.us/l/htbYcMvowT
StockInvest_us
Posted - 2 months ago
Signal alert: $COLL - Double Top https://stockinvest.us/l/DHH2XjDAmb
DonCorleone77
Posted - 2 months ago
$COLL Collegium raises FY24 revenue view to $620M-$635M from $580M-$595M FY24 revenue consensus $617.6M.
DonCorleone77
Posted - 2 months ago
$COLL Collegium Pharmaceutical completes acquisition of Ironshore for $525M in cash Collegium Pharmaceutical announced that it has completed the acquisition of Ironshore Therapeutics, a privately held company that markets and distributes Jornay PM, a central nervous system stimulant for the treatment of attention deficit hyperactivity disorder. Collegium also updated its 2024 financial guidance to include the anticipated impact of the Ironshore acquisition. Under the terms of the agreement, Collegium acquired all the outstanding shares of Ironshore for $525 million in cash, which was funded by $200 million of Collegium's existing cash on hand and $325 million of Collegium's $646 million term loan provided by investment funds managed by Pharmakon Advisors, LP. Collegium will also pay Ironshore shareholders $25 million in additional consideration if Jornay PM net revenue exceeds a defined threshold in 2025. The balance of the $646 million five-year term loan was used to repay Collegium's prior $320.8 million term loan, reducing Collegium's interest rate by 300 basis points.
Telefon
Posted - 2 months ago
$ELTP Elite Pharmaceuticals - Drugs Awaiting Launch and Total Market Value Methotrexate ($63.4M): Recently FDA approved, launching this quarter. Generic APAP with Codeine ($45M): Brand name Tylenol with Codeine, launching 6-8 weeks after Methotrexate. Oxy APAP ($500M): Generic Percocet, launching 6-8 weeks after APAP with Codeine. Hydro APAP ($477M): Generic Norco, launching after Oxy APAP. Methadone ($30M): Launching after Hydro APAP. Generic Vyvanse ($5.1B): Pending FDA approval, will take priority upon approval. Total Potential Market Value: $6.215 Billion $ORIC $COLL $TARS $PHAT